Notice2021-28479
William Kulakevich: Final Debarment Order
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 4, 2022
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring William Kulakevich for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Kulakevich was convicted of one felony count under Federal law for conspiracy to commit offenses against the United States. The factual basis supporting Mr. Kulakevich's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Kulakevich was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of September 16, 2021 (30 days after receipt of the notice), Mr. Kulakevich had not responded. Mr. Kulakevich's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 2 (Tuesday, January 4, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 2 (Tuesday, January 4, 2022)]
[Notices]
[Pages 225-226]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-28479]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0506]
William Kulakevich: Final Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is issuing an order
under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring
William Kulakevich for a period of 5 years from importing or offering
for import any drug into the United States. FDA bases this order on a
finding that Mr. Kulakevich was convicted of one felony count under
Federal law for conspiracy to commit offenses against the United
States. The factual basis supporting Mr. Kulakevich's conviction, as
described below, is conduct relating to the importation into the United
States of a drug or controlled substance. Mr. Kulakevich was given
notice of the proposed debarment and was given an opportunity to
request a hearing to show why he should not be debarred. As of
September 16, 2021 (30 days after receipt of the notice), Mr.
Kulakevich had not responded. Mr. Kulakevich's failure to respond and
request a hearing constitutes a waiver of his right to a hearing
concerning this matter.
DATES: This order is applicable January 4, 2022.
ADDRESSES: Submit applications for termination of debarment to the
Dockets Management Staff, Food and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, or at <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, Division of
Enforcement (ELEM-4029), Office of Strategic Planning and Operational
Policy, Office of Regulatory Affairs, Food and Drug Administration,
12420 Parklawn Dr., Rockville, MD 20857, 240-402-8743, or at
<a href="/cdn-cgi/l/email-protection#ee8a8b8c8f9c838b809a9dae888a8fc086869dc0898198"><span class="__cf_email__" data-cfemail="096d6c6b687b646c677d7a496f6d682761617a276e667f">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(1)(D) of the FD&C Act (21 U.S.C. 335a(b)(1)(D))
permits debarment of an individual from importing or offering for
import any drug into the United States if FDA finds, as required by
section 306(b)(3)(C) of the FD&C Act, that the individual has been
convicted of a felony for conduct relating to the importation into the
United States of any drug or controlled substance. On July 23, 2019,
Mr. Kulakevich was convicted, as defined in section 306(l)(1) of FD&C
Act, in the U.S. District Court for the Western District of
Pennsylvania, when the court entered judgment against him for the
offense of conspiracy to commit offenses against the United States, in
violation of 18 U.S.C. 2 and 371.
FDA's finding that debarment is appropriate is based on the felony
conviction referenced herein. The factual basis for this conviction is
as follows: As contained in the indictment in Mr. Kulakevich's case,
filed August 22, 2017, to which he plead guilty, from on or about April
2015, and continuing until May 2017, Mr. Kulakevich was the owner and a
co-operator of a website, <a href="http://www.etizy.com">www.etizy.com</a>, through which he sold and
distributed a drug known as etizolam to consumers throughout the United
States. Etizolam is a drug known as thienodiazepine, which is
chemically similar to benzodiazepines and carries risks of dependency,
toxicity, and the possibility of fatal overdose. Etizolam is not FDA-
approved in the United States. Mr. Kulakevich and his co-conspirator
illegally bought etizolam from an overseas supplier in India, after
which he arranged to have it smuggled into the United States through
the use of multiple post office boxes controlled by him and his
coconspirator. To avoid Federal regulators, Mr. Kulakevich used
[[Page 226]]
false and misleading labeling and generally misrepresented the nature
of the products sold on his website. Mr. Kulakevich reshipped the
misbranded etizolam to customers located in the United States.
As a result of this conviction, FDA sent Mr. Kulakevich, by
certified mail, on August 3, 2021, a notice proposing to debar him for
a 5-year period from importing or offering for import any drug into the
United States. The proposal was based on a finding under section
306(b)(3)(C) of the FD&C Act that Mr. Kulakevich's felony conviction
under Federal law for conspiracy to commit offenses against the United
States, in violation of 18 U.S.C. 2 and 371, was for conduct relating
to the importation into the United States of any drug or controlled
substance because he illegally imported, relabeled, and then introduced
unapproved etizolam products into interstate commerce. In proposing a
debarment period, FDA weighed the considerations set forth in section
306(c)(3) of the FD&C Act that it considered applicable to Mr.
Kulakevich's offense and concluded that the offense warranted the
imposition of a 5-year period of debarment.
The proposal informed Mr. Kulakevich of the proposed debarment and
offered him an opportunity to request a hearing, providing him 30 days
from the date of receipt of the letter in which to file the request,
and advised him that failure to request a hearing constituted a waiver
of the opportunity for a hearing and of any contentions concerning this
action. Mr. Kulakevich received the proposal and notice of opportunity
for a hearing on August 17, 2021. Mr. Kulakevich failed to request a
hearing within the timeframe prescribed by regulation and has,
therefore, waived his opportunity for a hearing and waived any
contentions concerning his debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Assistant Commissioner, Office of Human and Animal
Food Operations, under section 306(b)(3)(C) of the FD&C Act, under
authority delegated to the Assistant Commissioner, finds that Mr.
William Kulakevich has been convicted of a felony under Federal law for
conduct relating to the importation into the United States of any drug
or controlled substance. FDA finds that the offense should be accorded
a debarment period of 5 years as provided by section 306(c)(2)(A)(iii)
of the FD&C Act.
As a result of the foregoing finding, Mr. Kulakevich is debarred
for a period of 5 years from importing or offering for import any drug
into the United States, effective (see DATES). Pursuant to section
301(cc) of the FD&C Act (21 U.S.C. 331(cc)), the importing or offering
for import into the United States of any drug or controlled substance
by, with the assistance of, or at the direction of Mr. Kulakevich is a
prohibited act.
Any application by Mr. Kulakevich for termination of debarment
under section 306(d)(1) of the FD&C Act should be identified with
Docket No. FDA-2021-N-0506 and sent to the Dockets Management Staff
(see ADDRESSES). The public availability of information in these
submissions is governed by 21 CFR 10.20(j).
Publicly available submissions will be placed in the docket and
will be viewable at <a href="https://www.regulations.gov">https://www.regulations.gov</a> or at the Dockets
Management Staff (see ADDRESSES) between 9 a.m. and 4 p.m., Monday
through Friday, 240-402-7500.
Dated: December 28, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021-28479 Filed 1-3-22; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 4, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.